These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 9150811)

  • 1. Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.
    Myllylä VV; Sotaniemi KA; Hakulinen P; Mäki-Ikola O; Heinonen EH
    Acta Neurol Scand; 1997 Apr; 95(4):211-8. PubMed ID: 9150811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.
    Lees AJ
    BMJ; 1995 Dec; 311(7020):1602-7. PubMed ID: 8555803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of early selegiline therapy on long-term levodopa treatment and parkinsonian disability: an interim analysis of a Norwegian--Danish 5-year study. Norwegian-Danish Study Group.
    Larsen JP; Boas J
    Mov Disord; 1997 Mar; 12(2):175-82. PubMed ID: 9087975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis.
    Olanow CW; Myllylä VV; Sotaniemi KA; Larsen JP; Pålhagen S; Przuntek H; Heinonen EH; Kilkku O; Lammintausta R; Mäki-Ikola O; Rinne UK
    Neurology; 1998 Sep; 51(3):825-30. PubMed ID: 9748034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline slows the progression of the symptoms of Parkinson disease.
    Pålhagen S; Heinonen E; Hägglund J; Kaugesaar T; Mäki-Ikola O; Palm R;
    Neurology; 2006 Apr; 66(8):1200-6. PubMed ID: 16540603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease.
    Myllylä VV; Heinonen EH; Vuorinen JA; Kilkku OI; Sotaniemi KA
    Acta Neurol Scand; 1995 Mar; 91(3):177-82. PubMed ID: 7793231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
    Pålhagen S; Heinonen EH; Hägglund J; Kaugesaar T; Kontants H; Mäki-Ikola O; Palm R; Turunen J
    Neurology; 1998 Aug; 51(2):520-5. PubMed ID: 9710028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
    Ben-Shlomo Y; Churchyard A; Head J; Hurwitz B; Overstall P; Ockelford J; Lees AJ
    BMJ; 1998 Apr; 316(7139):1191-6. PubMed ID: 9583926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does selegiline modify the progression of early Parkinson's disease? Results from a five-year study. The Norwegian-Danish Study Group.
    Larsen JP; Boas J; Erdal JE
    Eur J Neurol; 1999 Sep; 6(5):539-47. PubMed ID: 10457386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of newly formulated selegiline orally disintegrating tablets as an adjunct to levodopa in the management of 'off' episodes in patients with Parkinson's disease.
    Lew MF; Pahwa R; Leehey M; Bertoni J; Kricorian G;
    Curr Med Res Opin; 2007 Apr; 23(4):741-50. PubMed ID: 17407630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.
    Shoulson I; Oakes D; Fahn S; Lang A; Langston JW; LeWitt P; Olanow CW; Penney JB; Tanner C; Kieburtz K; Rudolph A;
    Ann Neurol; 2002 May; 51(5):604-12. PubMed ID: 12112107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SELEDO: a 5-year long-term trial on the effect of selegiline in early Parkinsonian patients treated with levodopa.
    Przuntek H; Conrad B; Dichgans J; Kraus PH; Krauseneck P; Pergande G; Rinne U; Schimrigk K; Schnitker J; Vogel HP
    Eur J Neurol; 1999 Mar; 6(2):141-50. PubMed ID: 10053226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment.
    Heinonen EH; Rinne UK; Tuominen J
    Acta Neurol Scand Suppl; 1989; 126():113-8. PubMed ID: 2515716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study.
    Waters CH; Sethi KD; Hauser RA; Molho E; Bertoni JM;
    Mov Disord; 2004 Apr; 19(4):426-32. PubMed ID: 15077240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies in the treatment of Parkinson's disease.
    Hely MA; Morris JG
    Curr Opin Neurol; 1996 Aug; 9(4):308-13. PubMed ID: 8858190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early addition of selegiline to L-Dopa treatment is beneficial for patients with Parkinson disease.
    Mizuno Y; Kondo T; Kuno S; Nomoto M; Yanagisawa N
    Clin Neuropharmacol; 2010; 33(1):1-4. PubMed ID: 19935410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Parkinson's disease.
    Lieberman A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):339-43. PubMed ID: 8507903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
    Dubois B; Montastruc JL
    Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.